Jane Street Group LLC Sells 69,415 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Jane Street Group LLC cut its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 74.5% in the 3rd quarter, HoldingsChannel reports. The fund owned 23,731 shares of the biotechnology company’s stock after selling 69,415 shares during the period. Jane Street Group LLC’s holdings in Aldeyra Therapeutics were worth $128,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ALDX. US Bancorp DE bought a new stake in Aldeyra Therapeutics in the 3rd quarter worth about $30,000. Paloma Partners Management Co purchased a new position in Aldeyra Therapeutics in the third quarter valued at about $62,000. King Wealth Management Group boosted its holdings in Aldeyra Therapeutics by 24.5% in the 3rd quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock worth $74,000 after buying an additional 2,700 shares during the period. BNP Paribas Financial Markets boosted its holdings in Aldeyra Therapeutics by 253.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 14,229 shares of the biotechnology company’s stock worth $77,000 after buying an additional 10,201 shares during the period. Finally, Intech Investment Management LLC bought a new position in Aldeyra Therapeutics in the 3rd quarter worth approximately $79,000. 59.71% of the stock is owned by institutional investors.

Aldeyra Therapeutics Price Performance

Shares of NASDAQ:ALDX opened at $4.77 on Tuesday. The firm has a fifty day moving average price of $4.98 and a two-hundred day moving average price of $4.94. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. Aldeyra Therapeutics, Inc has a one year low of $2.71 and a one year high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25). As a group, equities analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current year.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.